US Patent Issued to SINGAPORE HEALTH SERVICES on June 3 for "THREONINE166 and SERINE189 of rubicon run domain as LRRK2 kinase inhibition target sites" (Singaporean Inventors)

ALEXANDRIA, Va., June 4 -- United States Patent no. 12,319,733, issued on June 3, was assigned to SINGAPORE HEALTH SERVICES PTE LTD (Singapore).

"THREONINE166 and SERINE189 of rubicon run domain as LRRK2 kinase inhibition target sites" was invented by Lai Ling Sharon Chan (Singapore) and Eng King Tan (Singapore).

According to the abstract* released by the U.S. Patent & Trademark Office: "Method of detecting phosphorylation at Threonine 166 of a Rubicon protein to identify a subject having a disease associated with Leucine-rich repeat kinase 2 (LRRK2) such as Parkinson's disease and compounds and methods for treating the same."

The patent was filed on March 6, 2020, under Application No. 17/436,951.

*For further information, including im...